<DOC>
	<DOCNO>NCT00002153</DOCNO>
	<brief_summary>To evaluate topical A-007 patient advanced malignancy include Kaposi 's sarcoma lymphoproliferative disorder .</brief_summary>
	<brief_title>Topical Use 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone ( A-007 ) Treatment Advanced Malignancies Including Kaposi 's Sarcoma Lymphoproliferative Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Maintenance antihormones , hormone , glucocorticoid . Patients must : Histologically proven metastatic cancer include Kaposi 's sarcoma lymphoproliferative disorder skin cutaneous site . NOTE : Primary basal squamous cell cancer skin allow . Failed primary secondary chemotherapy and/or immunotherapy protocol . Measurable skin cutaneous lesion . 4 Life expectancy least 20 week . Prior Medication : Required : Prior therapy cutaneous lesion Kaposi 's sarcoma lymphoproliferative disorder . Allowed : Prior maintenance steroid hormone/antihormone therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active infection medically stable HIV infection . Active congestive heart failure , persistent arrhythmia transient serious arrhythmia ( ventricular tachycardia , sinoatrial arrest , etc . ) , progressive cardiomyopathy . Unstable blood pressure . Seizures CNS disorder . Severe unstable diabetes mellitus . Coagulopathies . Thrombotic disease . Any medical condition would prevent completion study produce significant risk patient . Concurrent Medication : Excluded : Concomitant chemotherapy immunotherapy . Ongoing corticosteroid therapy ( unless maintenance ) . Patients follow prior condition exclude : History active cardiopulmonary respiratory disease . History sun hypersensitivity photosensitive dermatosis . History allergy hypersensitivity cosmetic , toiletry , dermatological product .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Skin Neoplasms</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>